"I am thrilled that the CREATE technology developed in my lab is being commercialized by Muse bio under its exclusive license," said Ryan Gill, Professor of Chemistry at University of Colorado, and Chief Science Officer and a co-founder at Muse bio. "Through incorporation of the CREATE technology into ForgeCraft, academic, industrial, agricultural and biopharma researchers worldwide will be able to significantly accelerate the time it takes to explore genotype-phenotype relationships and the development of valuable and sustainable products."
"Never before has the full biological complexity of an organism's genetic landscape been made so accessible for exploration and engineering," said Kevin Ness, Chief Executive Officer at Muse bio. "Muse bio is committed to deliver a much-needed platform for genome engineering to enable high throughput editing of genomes."
The paper titled "Genome-wide mapping of mutations at a single-nucleotide resolution for protein, metabolic and genome engineering" was published on-line this week in Nature Biotechnology and can be viewed on-line at http://www.nature.com/nbt/journal/vaop/ncurrent/full/nbt.3718.html.
Muse bio is enabling a new era of genome engineering that will transform our understanding of biology. Muse bio delivers power to researchers and production scientists in the field of genome engineering and synthetic biology through the combination of a powerful computer-aided forward design software package, a proprietary benchtop biofoundry and associated reagents. Its next-generation, CRISPR-based ForgeCraft technology dramatically accelerates genome engineering. For more information, please visit www.musebio.com.
To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/nature-biotechnology-paper-details-high-throughput-multiplexed-crispr-technology-300378840.html
SOURCE Muse bio